Tetra Bio-Pharma Inc. (TBPMF)
Chart Events
Performance Outlook
| Previous Close | 0.0439 |
| Open | 0.0372 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0372 - 0.0456 |
| 52 Week Range | 0.0372 - 0.2750 |
| Volume | |
| Avg. Volume | 98,122 |
| Market Cap | 19.287M |
| Beta (5Y Monthly) | 1.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0840 |
| Earnings Date | Apr 13, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for TBPMF
Related Research
- TETRA BIO PHARMA INCThe Argus Dividend Growth Model PortfolioDividend income, an important element of total return, is often overlooked amid gyrations in the stock market. Between 1930 and 2012, dividend income accounted for 42% of the total return of the S&P 500, according to Hartford Funds. And that's just the average. In some decades, dividends accounted for more than 50% of total returns and even 100% of returns. More recently, dividends have accounted for 15%-20% of returns. Still, in 2018, dividend payments softened the blow when most market indices declined as the Federal Reserve hiked rates. The pattern is being repeated in 2022 as well. Not all dividends are created equal, though, and it is important to understand the difference between the two main categories: high-yield stocks and dividend-growth stocks.RatingFair ValueEconomic Moat5 days agoArgus Research
- PR Newswire
Tetra Bio-Pharma Opens New Subsidiary in Australia and Provides Regulatory Update
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announces the launch of its new wholly owned subsidiary 'Tetra Bio-Pharma Australia Pty Ltd' ("TBP-AU"), an Australian-based research company focused on the execution of clinical trials in Australia. This represents Tetra's second foreign subsidiary and is in line with the Company's global expansion strategy for QIXLEEF™, and other future drug can
- PR Newswire
Tetra Bio-Pharma Announces Voting Results of 2022 Annual General and Special Meeting
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, held its annual general and special meeting (the "Meeting") of its holders of common shares (the "Shareholders") virtually on May 30, 2022. The Company is pleased to announce that all matters presented for approval at the Meeting were approved, except with respect to the proposed share consolidation of the issued and outstanding common shares of
- PR Newswire
Tetra Bio-Pharma Appoints Chief Financial Officer
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1) a leader in cannabinoid-derived drug discovery and development is pleased to announce the appointment of Leslie Auld, H.BSc, MBA, CPA, as Chief Financial Officer and member of the Company's executive team, effective May 30, 2022.
